New treatment option for neovascular age-related macular degeneration

04 August 2026 by Wendy WINN (DG SANTE, European Commission)

The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union for Susvimo (ranibizumab) to treat adults with neovascular (wet) age-related macular degeneration (nAMD). It is for use only in combination with a refillable implant surgically inserted into...

Register to the Health Policy Platform

See full publication (Platform members only)